Literature DB >> 7286461

Intrahepatocytic copper and copper-binding protein in primary biliary cirrhosis. Discrimination from chronic active hepatitis by means of orcein and rubeanic acid techniques.

M Lesna, A N Hamlyn, A J Watson.   

Abstract

Liver tissue samples from 111 patients with various hepatic disorders including 37 with primary biliary cirrhosis (PBC) and 22 with chronic active hepatitis (CAH) were studied. Of the PBC patients, 33 out of 37 (89%) showed orcein-positive and rubeanic acid-positive intrahepatocytic copper granules. In the 4 negative cases conventional staining methods revealed characteristic bile duct lesions and granuloma formations; all 4 were so-called presymptomatic patients. Amongst the liver biopsy samples from CAH patients, 12 out of 22 (55%) contained orcein-positive granules, but none showed stainable copper. We conclude that (1) combined orcein and rubeanic acid positivity in liver samples helps to distinguish between PBC and CAH; (2) in presymptomatic PBC the negativity of both methods is adequately compensated by a high frequency of characteristic bile duct lesions and granuloma formation: (3) the absence of orceinophilic intrahepatocytic granules, in our hands, does not accurately predict the response to steroid therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7286461     DOI: 10.1159/000198615

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  2 in total

1.  Three stages of copper accumulation in hepatocellular lysosomes: X-ray microanalysis of copper-loaded golden hamsters.

Authors:  A Yagi; H Hayashi; T Higuchi; N Hishida; N Sakamoto
Journal:  Int J Exp Pathol       Date:  1992-02       Impact factor: 1.925

2.  Autoimmune hepatitis: review of histologic features included in the simplified criteria proposed by the international autoimmune hepatitis group and proposal for new histologic criteria.

Authors:  Dana Balitzer; Nafis Shafizadeh; Marion G Peters; Linda D Ferrell; Najeeb Alshak; Sanjay Kakar
Journal:  Mod Pathol       Date:  2017-01-20       Impact factor: 7.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.